Navigation Links
Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Date:10/31/2007

SAN FRANCISCO, Oct. 31 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Tuesday, November 6, at 11:15 a.m. Eastern Time at the New York Palace Hotel.

Dr. Hung will provide an overview of Medivation and its clinical development programs for Dimebon(TM) for Alzheimer's and Huntington's diseases and MDV3100 for prostate cancer.

The Company reported results from its Phase 2 efficacy study of Dimebon in Alzheimer's disease in June 2007, showing that Dimebon improved the clinical course of patients by demonstrating meaningful improvement over placebo in each of the five disease aspects most important to patients, caregivers and physicians -- memory, thinking, activities of daily living, behavior and overall function. Significant gains in these disease aspects were evident as early as the twelfth week of treatment. After six months of treatment, patients were significantly better off than they were at the start of therapy on all key aspects of the disease. Dimebon's overall benefit compared to placebo continued to increase over time and was greater at 12 months that at six months.

A live audio webcast of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at http://www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical develo
'/>"/>

SOURCE Medivation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
(Date:9/30/2014)... 2014 The custom stainless steel fabrication ... Show 2014. The Boston Area Chapter of ISPE (International ... day-long event for Wed., Oct. 1 at Gillette Stadium ... the largest in ISPE Boston’s long history, with more ... attendees expected. , HOLLOWAY AMERICA President David Simpson ...
Breaking Biology Technology:Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... Polytechnic Institute have developed a new method to harvest ... the creation of self-powered microsensors for more accurate and ... Koratkar, the researchers investigated how the flow of water ... small amounts of electricity. The research team demonstrated the ...
... , , • NT-KO-003, developed by ... neuroprotective effects that does not cause,immunosuppression. ... administered orally, whereas the few treatments available in,Spain require ... • NeuroAdvan, the Phase IIa clinical ...
... 2011 , Convergence Pharmaceuticals Limited ("Convergence"), ... value analgesic,medicines, today announces that the Phase II proof ... lumbosacral,radiculopathy (LSR) has started. LSR is a ... roots in the lumbar region of the spine. Common,features ...
Cached Biology Technology:New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 2New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 2Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 3Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 4
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
(Date:9/29/2014)... a new Food and Brand Lab pilot study, published ... in the National School Lunch Program (NSLP) by 9% ... , Chefs Move to Schools (CMTS), an initiative of ... in order to provide nutrition instruction to students and ... A CMTS event was held in an Upstate New ...
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Chefs move to schools can increase school meal participation and vegetable intake among students 2An apple a day could keep obesity away 2
... New studies released today underscore the potential impact ... of aging, and learning. The research focused on the ... presented at Neuroscience 2013, the annual meeting of the ... emerging news about brain science and health. The ...
... believed that microorganisms that produce methane swim toward the hydrogen ... too hard to prove in the lab. Montana State ... verify it for the first time, said Matthew Fields, an ... a new paper describing the find. In the process, ...
... tyrosine kinases are a large family of cell-surface ... signals, including insulin, growth factors such as epidermal ... and molecules involved in neuronal guidance. Ligand binding ... leading to recruitment of enzymes and adapter proteins ...
Cached Biology News:Research reveals roles for exercise and diet in aging, depression 2Montana State team overcomes challenges, proves that microbes swim to hydrogen gas 2
Request Info...
... The KingFisher magnetic particle based purification systems ... DNA/RNA from any sample. They offer increased ... comprises three systems- KingFisher, KingFisher mL and ... - 1000 l. Each system consists of ...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... PROTECT FROM MOISTURE. AVOID FREEZE/THAW CYCLES. ... cells in vitro by DNA ... their anti-histone-facilitated detection. In this assay, mono- ... binding proteins. Anti-Histone 3 (H3) biotin-labeled antibody ...
Biology Products: